CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Pfizer Inc. v. Hetero USA Inc.

1:13-cv-02021

Overview

Case Number 1:13-cv-02021
Filing Date 2013-12-11
Status Terminated
Termination Date 2015-07-01
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Hetero Labs Limited NPE (University / Research)

Represented By

2 Attorneys Listed

John M. Seaman

Abrams & Bayliss LLP

Tel: +1 (302) 778-1000
Fax: +1 (302) 573-3501

20 Montchanin Road, Suite 200

Thad J. Bracegirdle

Wilks, Lukoff & Bracegirdle, LLC

Tel: +1 (302) 225-0855
Fax: +1 (302) 225-0856

Wilks, Lukoff & Bracegirdle, LLC, 1300 N. Grant Avenue, Suite 100

Hetero USA Inc. Operating Company

Represented By

5 Attorneys Listed

John M. Seaman

Abrams & Bayliss LLP

Tel: +1 (302) 778-1000
Fax: +1 (302) 573-3501

20 Montchanin Road, Suite 200

Thad J. Bracegirdle

Wilks, Lukoff & Bracegirdle, LLC

Tel: +1 (302) 225-0855
Fax: +1 (302) 225-0856

Wilks, Lukoff & Bracegirdle, LLC, 1300 N. Grant Avenue, Suite 100

Matthew S. Murphy

Email: mmurphy@axinn.com

Delphine Knight Brown

Email: dknightbrown@axinn.com

Chad A. Landmon

Email: clandmon@axinn.com

Plaintiff

UCB Pharma GmbH NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Pfizer Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials 8 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡©πŸ‡ͺ Germany πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (17 found):
PTAB: 8 U.S. Courts: 9
USPTO PTAB Trial 2016-08-22
IPR2016-01665

Amerigen Pharmaceuticals Limited et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (6858650)
Status: Final Written Decision
USPTO PTAB Trial 2016-08-22
IPR2016-01596

Alembic Pharmaceuticals Limited v. UCB Pharma GmbH

U.S. Continuation Sibling (6858650)
Status: Final Written Decision
USPTO PTAB Trial 2016-08-18
IPR2016-01636

Torrent Pharmaceuticals Limited et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (6858650)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00512

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (7384980)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00517

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00516

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (8338478)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00514

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (7855230)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00510

Mylan Pharmaceuticals Inc et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (6858650)
Status: Final Written Decision
U.S. District Court 2015-11-18
1:15-cv-01067

Pfizer Inc. v. Dr. Reddy's Laboratories Ltd.

Asserted Patent
Status: DED
U.S. District Court 2013-12-11
1:13-cv-02022

Pfizer Inc. v. Apotex Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-08-02
1:13-cv-01387

Pfizer Inc. v. Wockhardt Bio AG

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01155

Pfizer Inc. v. Accord Healthcare Inc.USA

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01158

Pfizer Inc. v. Impax Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01153

Pfizer Inc. v. Lupin Ltd

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01154

Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01156

Pfizer Inc. v. Amerigen Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-06-21
1:13-cv-01111

Pfizer Inc. v. Sandoz Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6858650
Stable salts of novel derivatives of 3,3-diphenylpropylamines
Filed: 2000-11-15
Issued: 2005-02-22
Expired (Term Ended) +1149d PTA
Expires: 2024-01-08
US7384980
Derivatives of 3,3-diphenylpropylamines
Filed: 2005-08-10
Issued: 2008-06-10
Expired (Term Ended)
Expires: 2019-10-14
US7855230
Derivatives of 3,3-diphenylpropylamines
Filed: 2008-04-17
Issued: 2010-12-21
Expired (Term Ended)
Expires: 2019-08-17
US7985772
Derivatives of 3,3-diphenylpropylamines
Filed: 2010-06-14
Issued: 2011-07-26
Active (3.6 yrs remaining)
Expires: 2030-06-14
US8338478
Derivatives of 3,3-diphenylpropylamines
Filed: 2011-06-15
Issued: 2012-12-25
Active (4.6 yrs remaining)
Expires: 2031-06-15

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1149 days) / Cellect Scrutiny β€” Over 1149 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(27 total)
Pleading / Complaint

COMPLAINT filed against Hetero Labs Limited, Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1423621.) - filed by UCB Pharma GmbH, Pfizer Inc.. (Attachments: # 1 Exhibit A-E part 1, # 2 Exhibit A-E part 2, # 3 Exhibit A-E part 3, # 4 Civil Cover Sheet)(cla, ) (Entered: 12/12/2013)

Entry #1 • 2013-12-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cla, ) (Entered: 12/12/2013)

Entry #2 • 2013-12-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/29/13. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 5/1/2016. (cla, ) (Entered: 12/12/2013)

Entry #3 • 2013-12-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,858,650 B1; 7,384,980 B2; 7,855,230 B2; 7,985,772 B2; 8,338,478 B2;. (cla, ) (Entered: 12/12/2013)

Entry #4 • 2013-12-11
1

Disclosure Statement pursuant to Rule 7.1 filed by Pfizer Inc., UCB Pharma GmbH identifying Corporate Parent UCB S.A., Corporate Parent UCB GmbH for UCB Pharma GmbH. (cla, ) (Entered: 12/12/2013)

Entry #5 • 2013-12-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc